Shares of ArQule (ARQL +2.4%) move up after the company says it's enrolled the first patient in...

|By:, SA News Editor

Shares of ArQule (ARQL +2.4%) move up after the company says it's enrolled the first patient in its Phase 3 trial of tivantinib, which is being evaluated for the treatment of patients diagnosed with hepatocellular carcinoma who have received one or two prior systemic anti-cancer therapies. The company expects to enroll about 300 patients at approximately 120 clinical centers worldwide.